Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent…
$31.59-0.54%
报价 2026-11-13
市值
$1.89B
EV
$2.02B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -30.6%
$22.34$45.49
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| AGIOAgios Pharmaceuticals, Inc. | $1.89B | -0.5% | +295.0% | 87.9% | – | – | – | |
| IBRXImmunityBio, Inc. | $6.4B | -0.8% | +77.3% | 94.6% | – | – | – | |
| LQDALiquidia Corporation | $5.17B | -1.2% | +366.9% | 92.5% | 30.2x | 23.0x | 70.1x | |
| COGTCogent Biosciences, Inc. | $4.97B | -2.0% | +260.0% | 0% | – | – | – | |
| DNLIDenali Therapeutics Inc. | $3B | -0.8% | +2004.0% | 0% | – | – | – | |
| RCUSArcus Biosciences, Inc. | $2.51B | -1.9% | -70.6% | 97% | – | – | – | |
| BEAMBeam Therapeutics Inc. | $2.36B | -5.0% | +6.9% | 100% | – | – | – | |
| RXRXRecursion Pharmaceuticals, Inc. | $1.98B | -4.4% | -36.9% | -49.8% | – | – | – | |
| SRPTSarepta Therapeutics, Inc. | $1.72B | +0.4% | +0.2% | 58.6% | – | – | – | |
| 同行中位数 | – | – | +42.1% | 75.5% | 30.2x | 23.0x | 70.1x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。